[Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
Payan
C
C
Laboratoire de bactériologie-virologie, centre hospitalier universitaire, 4, rue Larrey, 49033 cedex 01, Angers, France. ChPayan@chu-angers.fr <ChPayan@chu-angers.fr>
Brault
C
C
Peigne
M
M
Loison
J
J
Chennebault
J-M
JM
D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D003521:Cyclopropanes; D024921:Drug Resistance, Multiple, Viral; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology / Q000627:therapeutic use; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use; D016133:Polymerase Chain Reaction / Q000295:instrumentation / Q000379:methods*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use; D018119:Stavudine / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000821:virology*; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D018119:Stavudine; C098320:efavirenz; D019438:Ritonavir